 Scientists at McMaster University and the University of Toronto have developed a CAR-T therapy targeting CD133 for aggressive brain cancer glioblastoma. The CAR-Ts are showing promise in mouse models, leading to the formation of a new biotech called Empirica Therapeutics. 